Lookup NU author(s): Dr Ioannis Kotsopoulos,
Dr Asima Mukhopadhyay,
Professor John Lunec,
Professor Nicola Curtin
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Treatment options for disease recurrence of women treated for locally advanced and advanced cervical cancer are very limited largely palliative chemotherapy. The low efficacy of the currently available drugs raises the need for new targeted agents. Poly(adeno sine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors (PARPi) have emerged as a promising class of chemotherapeutic agents in cancers associated with defects in DNA repair. Their therapeutic potential in cervical cancer is currently being evaluated in 3 ongoing clinical trials. Here we review the available information regarding all the aspects of PARP in cervical intraepithelial neoplasia and invasive cervical cancer, from expression and the mechanism of action to the role of the polymorphisms in the pathogenesis of the disease, as well as the potential of the inhibitors. We finally propose a new unifying theory regarding the role of PARPs in the development of cervical carcinomas.
Author(s): Kotsopoulos IC, Kucukmetin A, Mukhopadhyay A, Lunec J, Curtin NJ
Publication type: Review
Publication status: Published
Journal: International Journal of Gynecological Cancer
Print publication date: 01/05/2016
Acceptance date: 01/01/1900
ISSN (print): 1048-891X
ISSN (electronic): 1525-1438
Publisher: LIPPINCOTT WILLIAMS & WILKINS